Abstract:Alzheimer's disease (AD) is a typical protein-misfolding disease. Aggregation of amyloid β-peptide (Aβ) plays a key role in the etiology of AD. The misfolding of Aβ results in the formation of β-sheet-rich aggregates and damages the function of neurons. A modified polyoxometalate (POM), [CoL(H2O)]2[CoL]2[HAsVMoV6MoVI6O40] [CAM, L = 2-(1 H-pyrazol-3-yl)pyridine], was designed to disaggregate the Aβ aggregates, where L acts as an Aβ-targeting group and POM as a conformational modulator. X-ray crystallography shows that CAM is composed of a ε-Keggin unit and four coordination units. CAM can disaggregate the β-sheet-rich fibrils and metal-induced or self-aggregated Aβ aggregates, and it further inhibits the production of ROS; as a result, it can protect the neurons from synaptic toxicity induced by Zn2+- or Cu2+-Aβ aggregates or Aβ self-aggregation. The mechanism of disaggregation involves a transformation of Aβ conformation from β-sheet to other conformers. The nature of the process is an interference of the β-sheet conformation by CAM via hydrogen bonding. CAM specifically interacts with Aβ aggregates but does not disturb the cerebral metal homeostasis and enzymatic systems. Molecular simulation suggests that the appropriate size of CAM and the cavity of β-sheets facilitate the interaction between CAM and Aβ aggregates; additionally, the H-bonding-favored amino acid residues in the cavity provide a precondition for the interaction. Moreover, CAM is lipophilic and capable of penetrating the blood-brain barrier, and it is metabolizable without causing an untoward effect to mice at high dosages. In view of the significant inhibitory effect on the Aβ aggregation and related neurotoxicity, CAM represents a new type of leading compounds with a distinctive mechanism of action for the treatment of Alzheimer' disease. The conception of this study may be applied to other protein-misfolding diseases caused by conformational changes.

Enantioselective Modulation of Amyloid Burden and Memory Deficits by Chiral Polyoxometalates for Alzheimer's Disease Treatment

Design, Synthesis and Biological Evaluation of 2-Styryl-5-hydroxy-4-pyrone Derivatives and Analogues As Multiple Functional Agents with the Potential for the Treatment of Alzheimer's Disease.

Chiral Metallohelical Complexes Enantioselectively Target Amyloid Β for Treating Alzheimer’s Disease

Mo polyoxometalate nanoclusters capable of inhibiting the aggregation of Aβ-peptide associated with Alzheimer's disease.

Self‐Assembled Peptide–Polyoxometalate Hybrid Nanospheres: Two in One Enhances Targeted Inhibition of Amyloid Β‐peptide Aggregation Associated with Alzheimer's Disease

Chiral gold nanoparticles enantioselectively rescue memory deficits in a mouse model of Alzheimer’s disease

A New Chiral Pyrrolyl Alpha-Nitronyl Nitroxide Radical Attenuates Beta-Amyloid Deposition And Rescues Memory Deficits In A Mouse Model Of Alzheimer Disease

Peptide‐Modified Mo Polyoxometalate Nanoparticles Suppress Zn2+‐Induced Aβ Aggregation

Recent advance on pleiotropic cholinesterase inhibitors bearing amyloid modulation efficacy

Chiral Penicillamine-Modified Selenium Nanoparticles Enantioselectively Inhibit Metal-Induced Amyloid Β Aggregation for Treating Alzheimer’s Disease

Enantiomers of Cysteine-Modified SeNPs (d/lsenps) As Inhibitors of Metal-Induced Aβ Aggregation in Alzheimer's Disease.

Aspartic Acid-Modified Phospholipids Regulate Cell Response and Rescue Memory Deficits in APP/PS1 Transgenic Mice

Chiral LVFFARK Enantioselectively Inhibits Amyloid-Β Protein Fibrillogenesis

Nanomaterials for Modulating the Aggregation of -Amyloid Peptides

Metallosupramolecular Complex Targeting an Alpha/Beta Discordant Stretch of Amyloid Beta Peptide

A Chiral Nanocomplex for Multitarget Therapy to Alleviate Neuropathology and Rescue Alzheimer's Cognitive Deficits

Modulating Conformation of Aβ-Peptide: an Effective Way to Prevent Protein-Misfolding Disease

Multifunctional Nanorods Based on Self-Assembly of Biomimetic Apolipoprotein E Peptide for the Treatment of Alzheimer's Disease.

Copolymer Polydopamine Nanoparticles as Multifunctional Nanoinhibitors for Modulating β-Amyloid Aggregation

Ache Inhibition-Based Multi-Target-Directed Ligands, A Novel Pharmacological Approach for the Symptomatic and Disease-Modifying Therapy of Alzheimer'S Disease

Novel and Potent Acetylcholinesterase Inhibitors for the Treatment of Alzheimer's Disease from Natural ()-7,8-Dihydroxy-3-methyl-isochroman-4-one